Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy

被引：31

作者：

Hessel F.P. ^{[1
,5
]}

Wegner C. ^{[2
]}

Müller J. ^{[3
]}

Glaveris C. ^{[4
]}

Wasem J. ^{[1
]}

机构：

[1] University of Duisburg-Essen, Essen

[2] German Heart Institute, Berlin

[3] Clinic for Internal Medicine, Offenbach

[4] Institute for Health Care Management, Faculty of Economics, University of Duisburg-Essen, 45117 Essen

来源：

The European Journal of Health Economics, formerly: HEPAC | 2004年 / 5卷 / 1期

关键词：

Autoantibodies; Cardiomyopathy; Cost-effectiveness; Survival;

D O I：

10.1007/s10198-003-0202-5

中图分类号：

学科分类号：

摘要：

Idiopathic dilated cardiomyopathy (DCM) is a life-threatening heart disease and a major reason for heart transplantations. The medical efficacy of immunoadsorption (IA) for DCM patients has been demonstrated in initial clinical studies. This prospective matched-case control study examined 5-year survival rates, direct medical costs, and cost-effectiveness in Germany (n=34) from a health-care system perspective. In a cost-effectiveness analysis costs per life year gained were calculated. Patients treated with IA showed a greater survival rate: 5-year survival rate in the intervention group was 82% vs. 41% in controls. Log rank statistics after Kaplan-Meier analysis of cumulated survival probability were highly significant. Initial intervention costs for IA were found to be € 28,400 per patient treated. Direct medical costs for a 5-year follow-up were € 128,600 per patient treated with IA and € 75,500 in controls. Considering only the actual survival time we calculated annual treatment costs of € 24,900 in the IA group and € 28,900 in controls. The cost-effectiveness ratio expressed in costs per life year gained was € 34,400. This is the first controlled study to perform 5-year survival analysis and economic evaluation of this new emerging technology for patients with DCM. Although high initial treatment costs for IA are incurred, the significantly better survival rates lead to reasonable costs per live year gained.

引用

页码：58 / 63

页数：5

共 19 条

[11]

Hirth R.A., Chernow M.E., Miller E., Fendrick A.M., Weissert W.G., Willingness to pay for a quality adjusted life year: In search of a standard, Med Decis Making, 20, pp. 332-342, (2000)

[12]

Hobbs F.D., Kenkre J.E., Roalfe A.K., Davis R.C., Hare R., Davis M.K., Impact of heart failure and left ventricular systolic dysfunction on quality of life: A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population, Eur Heart J, 23, pp. 1867-1876, (2002)

[13]

Hosenpud J.D., Bennett L.E., Keck B.M., Fiol B., Novick R.J., The registry of the International Society for Heart and Lung Transplantation. Fourteenth official report 1997, J Heart Lung Transplant, 16, pp. 691-712, (1997)

[14]

Junger J., Schellberg D., Kraemer S., Haunstetter A., Zugck C., Herzog W., Haass M., Health related quality of life in patients with congestive heart failure: Comparison with other chronic diseases and relation to functional variables, Heart, 87, pp. 235-241, (2002)

[15]

Mann D.L., Autoimmunity, immunoglobulin adsorption and dilated cardiomyopathy: Has the time come for randomized clinical trials?, J Am Coll Cardiol, 38, pp. 184-186, (2001)

[16]

Muller J., Wallukat G., Dandel M., Bieda H., Brandes K., Spiegelsberger S., Nissen E., Kunze R., Hetzer R., Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy, Circulation, 101, pp. 385-391, (2000)

[17]

Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I., Martin I., Nordet P., Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies, Circulation, 93, pp. 841-842, (1996)

[18]

Schimke I., Muller J., Priem F., Kruse I., Schon B., Stein J., Kunze R., Wallukat G., Hetzer R., Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption, J Am Coll Cardiol, 38, pp. 178-183, (2001)

[19]

Tamburro P., Wilber D., Sudden death in idiopathic dilated cardiomyopathy, Am Heart J, 124, pp. 1035-1045, (1992)

← 1 2 →